GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) today announced pre-clinical research demonstrating the ability of the Company’s new adenovector, Ad35, to induce and sustain protein production in the eye. Lisa L. Wei, Ph.D., GenVec’s Director of Pre-Clinical Research, presented a poster, Alternate Serotype Adenovector Gives Long-Term Expression in the Eye, at the Association for Research in Vision and Ophthalmology (“ARVO”) Annual Meeting in Fort Lauderdale, Florida.
